Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
Amryt Pharma's online communities are open to the public. Anything posted to our social networks may be seen and read by everyone. We cannot be responsible for views expressed other than our own. By posting on Amryt Pharma's social media pages, you grant us the right to use or reproduce your content.
We welcome questions and commentary, including constructive feedback and differing opinions, but please remember to be both relevant and respectful with what you post. We do not tolerate harassment, abuse, or threats to others. We reserve the right to remove any posts that don’t adhere to our guidelines and to block anyone who violates them repeatedly.
Learn more about our community guidelines here:
https://amrytpharma.com/social-media-guidelines/
Company Details
- Employees
- 108
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://chiesirarediseases.com/
Amryt Pharma Questions
Amryt Pharma's website is https://chiesirarediseases.com/
Amryt Pharma's LinkedIn profile is https://www.linkedin.com/company/amryt-pharma
Amryt Pharma has
108 employees.
View email and phone details for 108
employees at Amryt Pharma.
Amryt Pharma's industry is
Biotechnology Research
Amryt Pharma's top competitors are
Serb Pharmaceuticals,
Alnylam Pharmaceuticals,
Saudi Society Of Clinical Pharmacy,
Alexion Pharmaceuticals, Inc.,
Poolbeg Pharma Plc,
Chiesi Usa, Inc.,
Kite Pharma,
Chiesi Group,
Ipsen,
Vertex Pharmaceuticals.
Amryt Pharma's categories are Biotechnology Research
Amryt Pharma's founding year is 2015
